EGFR and non-small cell lung carcinoma: Considerable efforts are underway to explore the concept of synthetic lethality to identify additional dependencies in classical mutant EGFR-driven models that can be targeted to overcome drug resistance.97 An unresolved question is whether EGFR exon 20 insertion-driven NSCLC will share similar downstream signaling profiles and vulnerabilities that can be exploited therapeutically.